Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Viz.ai has announced a multi-year partnership with Sanofi (SNY) and Regeneron (REGN) to develop and evaluate an AI-powered workflow solution for Chronic Obstructive Pulmonary Disease (COPD). The collaboration will focus on deploying the Viz COPD module, which uses electronic health record (EHR) data and artificial intelligence to improve detection and management of high-risk COPD patients.
The solution will be implemented across Viz.ai's network of over 1,700 hospitals and health systems, reaching more than 60,000 healthcare providers. COPD, affecting an estimated 392 million people globally and ranking as the fourth leading cause of death worldwide, remains underprioritized and undertreated. The AI-powered system will screen and triage patients using natural language processing, aligning with established clinical guidelines to identify high-risk individuals requiring follow-up care.
At the 75th Regeneron International Science and Engineering Fair (ISEF), nearly 1,700 young scientists from 48 U.S. states and 60+ countries competed for over $9 million in awards. The top prize, the $100,000 George D. Yancopoulos Innovator Award, went to Adam Kovalčík from Slovakia for developing a more efficient and cost-effective method to produce the antiviral drug galidesivir, reducing production costs from $75/gram to $12.50/gram.
Other major winners included Benjamin Davis ($75,000) for a desktop plastic recycling system, Siyaa Poddar ($75,000) for toxic dust detection technology, and a team of three students ($50,000) for developing a brain-controlled bionic prosthetic leg. The competition, sponsored by Regeneron Pharmaceuticals (NASDAQ: REGN), celebrated its milestone 75th year of fostering STEM innovation and has provided STEM experiences to over 3.2 million students since 2020.
- New data from the Phase 3 C-POST trial evaluating Libtayo in post-surgical high-risk cutaneous squamous cell carcinoma (CSCC)
- Initial results from LINKER-MM2 trial exploring combinations of linvoseltamab (BCMAxCD3 bispecific antibody) with carfilzomib or bortezomib in relapsed/refractory multiple myeloma
The presentations will cover multiple cancer types including non-melanoma and melanoma skin cancer, lung cancer, lymphoma, and multiple myeloma. Notable updates include results from a Phase 2 trial of vidutolimod combined with anti-PD-1 therapy in melanoma. The FDA is currently reviewing Biologics License Applications for linvoseltamab and odronextamab, with target action dates of July 10 and July 30, 2025, respectively.
Regeneron reported Q1 2025 financial results with total revenues of $3.0 billion, showing mixed performance across its product portfolio. Dupixent global sales grew 19% to $3.67 billion, while EYLEA HD U.S. sales increased 54% to $307 million.
Key highlights include:
- FDA approval of Dupixent for chronic spontaneous urticaria
- Japanese approval for Dupixent in COPD treatment
- EU approval of Lynozyfic for multiple myeloma
- Priority review status for EYLEA HD in retinal vein occlusion
The company announced over $7 billion in planned investments for New York and North Carolina infrastructure. Financial metrics showed GAAP diluted EPS of $7.27 and non-GAAP EPS of $8.22. While total EYLEA franchise sales declined 26% to $1.04 billion, the company maintains a robust pipeline with approximately 45 product candidates in clinical development.
Regeneron Pharmaceuticals (NASDAQ: REGN) has received conditional marketing approval from the European Commission for Lynozyfic™ (linvoseltamab), a novel bispecific antibody for treating relapsed/refractory multiple myeloma. The approval targets adult patients who have undergone at least three prior therapies and shown disease progression.
The LINKER-MM1 trial (n=117) demonstrated strong efficacy with a 71% objective response rate and 50% of patients achieving complete response or better. The median duration of response was 29 months. Lynozyfic features a unique response-adapted dosing schedule allowing administration every four weeks if specific response criteria are met after 24 weeks of therapy.
The most common adverse reactions included musculoskeletal pain (52%), cytokine release syndrome (46%), and neutropenia (43%). A U.S. FDA decision is expected by July 10, 2025.